EGFR and non-small cell lung carcinoma: Many of the current guidelines recommend the 3G TKI osimertinib as a front-line treatment for EGFR-mutated NSCLC patients, as a result of the significant improvement in prolonged progression-free and overall survival with osimertinib compared with 1G EGFR-TKIs in the FLAURA Phase III trial [2,13].